Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP-2202
- Development stage
- Preclinical
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP-2202 is a fixed-dose combination drug candidate under development by Hanmi Pharmaceutical for the treatment of unspecified cardiovascular disorders, gastric ulcers, and duodenal ulcers. It consists of two components, RLD2202 and RLD2203. The drug has undergone Phase 1 clinical trials to evaluate its pharmacokinetic characteristics and safety in healthy volunteers under both fasting and fed conditions. As of the latest available data, it remains in preclinical or early clinical development stages for its primary indications[1][2][3][4].
- Brand names
- Rabpirin
- Other names
- aspirin + rabeprazole sodium
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on HCP-2202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP-2202.